The structural and functional role of myelin fast-migrating cerebrosides: Pathological importance in multiple sclerosis

Clinical Lipidology

Volumn 6, Issue 2, 2011, Pages 159-179

  Podbielska, Maria ^a,b   Levery, Steven B ^c   Hogan, Edward L ^a,d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

anergy; fast migrating cerebrosides; glycosphingolipids; multiple sclerosis; myelin; NKT cells

Indexed keywords

3 O ACETYL SPHINGOSINE 2,3,4,6 TETRA O ACETYLGALACTOSYLCERAMIDE; 3 O ACETYL SPHINGOSINE GALACTOSYLCERAMIDE; ACETIC ACID DERIVATIVE; ALPHA GALACTOSYLCERAMIDE; CARBOHYDRATE DERIVATIVE; CD1 ANTIGEN; CD1B ANTIGEN; GALACTOSYLCERAMIDE; GAMMA INTERFERON; GANGLIOSIDE; GLYCOSIDASE; GLYCOSPHINGOLIPID; HEXAACETYLATED 3 O ACETYL SPHINGOSINE 2,3,4,6 TETRA O ACETYLGALACTOSYLCERAMIDE; MYELIN; MYELIN ACETYLCEREBROSIDE; MYELIN FAST MIGRATING CEREBROSIDE DERIVATIVE; PHOSPHOLIPID; SULFATIDE; T6 ANTIGEN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL COMPOSITION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; CHEMICAL STRUCTURE; CLONAL ANERGY; CROSS REACTION; DRUG MECHANISM; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOGENESIS; LIPID ANALYSIS; LYMPHOCYTE PROLIFERATION; MOLECULAR MIMICRY; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELINATION; NATURAL KILLER CELL; NEUROPATHOLOGY; NEUROPATHY; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; RADICULOPATHY; REGULATORY T LYMPHOCYTE; REVIEW;

TETRA;

EID: 79953815595     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.11.8     Document Type: Review

References (210)

1. Rosetti CM, Maggio B, Oliveira RG: The self-organization of lipids and proteins of myelin at the membrane interface. Molecular factors underlying the microheterogeneity of domain segregation. Biochim. Biophys. Acta 1778(7-8), 1665-1675 (2008).
2. Norton WT, Autilio LA: The lipid composition of purified bovine brain myelin. J. Neurochem. 13(4), 213-222 (1966).
3. Fewster ME, Hirono H, Mead JF: Lipid composition of myelin in multiple sclerosis. J. Neurol. 213(2), 119-131 (1976).
4. Dasgupta S, Levery SB, Hogan EL: 3-O-acetyl-sphingosine-series myelin glycolipids: characterization of novel 3-O-acetyl-sphingosine galactosylceramide. J. Lipid Res. 43(5), 751-761 (2002). First description of the acetylated derivatives of galactosylceramide.
5. Bennion B, Dasgupta S, Hogan EL, Levery SB: Characterization of novel myelin components 3-O-acetyl-sphingosine galactosylceramides by electrospray ionization Q-TOF MS and MS/CID-MS of Li+ adducts. J. Mass Spectrom. 42(5), 598-620 (2007).
6. Podbielska M, Dasgupta S, Levery SB et al.: Novel myelin penta- and hexa-acetylgalactosyl-ceramides: structural characterization and immunoreactivity in cerebrospinal fluid. J. Lipid Res. 51(6), 1394-1406 (2010). Description of the penta- and hexa-acetyl derivatives of galactosylceramide.
7. Xu L, Anchordoquy TJ: Cholesterol domains in cationic lipid/DNA complexes improve transfection. Biochim. Biophys. Acta 1778(10), 2177-2181 (2008).
8. + channels. Nature 451(7180), 826-829 (2008).
9. Yu RK, Ledeen RW: Gangliosides of human, bovine, and rabbit plasma. J. Lipid Res. 13(5), 680-686 (1972).
10. Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ: A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 131(Pt 11), 3092-3102 (2008).
11. Podbielska M, Hogan EL: Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult. Scler. 15(9), 1011-1029 (2009).
12. Kochetkov NK, Zhukova IG, Glukhoded IS: Sphingoplasmalogens. A new type of sphingolipids. Biochim. Biophys. Acta 70, 716-719 (1963).
13. Norton WT, Brotz M: New galactolipids of brain: a monoalkyl-monoacyl- glyceryl galactoside and cerebroside fatty acid esters. Biochem. Biophys. Res. Commun. 12, 198-203 (1963).
14. Kubota M, Taketomi T: Minor glycolipids being less polar than cerebroside in porcine spinal cord. Jpn J. Exp. Med. 44(2), 145-150 (1974).
15. Nudelman ED, Levery SB, Igarashi Y, Hakomori S: Plasmalopsychosine, a novel plasmal (fatty aldehyde) conjugate of psychosine with cyclic acetal linkage. Isolation and characterization from human brain white matter. J. Biol. Chem. 267(16), 11007-11016 (1992).
16. Levery SB, Nudelman ED, Hakomori S: Novel modification of glycosphingolipids by long-chain cyclic acetals: isolation and characterization of plasmalocerebroside from human brain. Biochemistry 31(23), 5335-5340 (1992).
17. Yachida Y, Kashiwagi M, Mikami T et al.: Stereochemical structures of synthesized and natural plasmalogalactosylceramides from equine brain. J. Lipid Res. 39(5), 1039-1045 (1998).
18. Klenk E, Lohr JP: On the ester cerebrosides of brain. Hoppe Seylers Z. Physiol. Chem. 348(12), 1712-1714 (1967).
19. Tamai Y: Further study on the faster running glycolipid in brain. Jpn J. Exp. Med. 38(1), 65-73 (1968).
20. Kishimoto Y, Wajda M, Radin NS: 6-acyl galactosyl ceramides of pig brain: structure and fatty acid composition. J. Lipid Res. 9(1), 27-33 (1968).
21. Dasgupta S, Everhart MB, Bhat NR, Hogan EL: Neutral monoglycosylceramides in rat brain: occurrence, molecular expression and developmental variation. Dev. Neurosci. 19(2), 152-161 (1997).
22. Dasgupta S, Bhat NR, Spicer SS, Hogan EL, Furuya S, Hirabayashi Y: Cell-specific expression of neutral glycosphingolipids in vertebrate brain: immunochemical localization of 3-O-acetyl-sphingosine-series glycolipid(s) in myelin and oligodendrocytes. J. Neurosci. Res. 85(13), 2856-2862 (2007).
23. Dupree JL, Girault JA, Popko B: Axo-glial interactions regulate the localization of axonal paranodal proteins. J. Cell Biol. 147(6), 1145-1152 (1999).
24. Suzuki K, Suzuki Y: Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside b-galactosidase. Proc. Natl Acad. Sci. USA 66(2), 302-309 (1970).
25. Suzuki K, Suzuki Y: Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe's diesease). In: The Metabolic Basis of Inherited Diesease. Stabury JC, Wyngaarden JB, Fredrikson DS, Goldstein JL, Brown MS (Eds). McGraw-Hill, NY, USA, 857-880 (1983).
26. Svennerholm L, Vanier MT, Mansson JE: Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J. Lipid Res. 21(1), 53-64 (1980).
27. Kobayashi T, Shinoda H, Goto I, Yamanaka T, Suzuki Y: Globoid cell leukodystrophy is a generalized galactosylsphingosine (psychosine) storage disease. Biochem. Biophys. Res. Commun. 144(1), 41-46 (1987).
28. Suzuki K, Suzuki K: The twitcher mouse. A model of human globoid cell leukodystrophy (Krabbe's disease). Am. J. Pathol. 111(3), 394-397 (1983).
29. Takahashi H, Igisu H, Suzuki K, Suzuki K: Murine globoid cell leukodystrophy (the twitcher mouse). The presence of characteristic inclusions in the kidney and lymph nodes. Am. J. Pathol. 112(2), 147-154 (1983).
30. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000).
31. Becher B, Bechmann I, Greter M: Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J. Mol. Med. 84(7), 532-543 (2006).
32. Mukherjee S, Soe TT, Maxfield FR: Endocytic sorting of lipid analogues differing solely in the chemistry of their hydrophobic tails. J. Cell Biol. 144(6), 1271-1284 (1999).
33. Mukherjee S, Maxfield FR: Role of membrane organization and membrane domains in endocytic lipid trafficking. Traffic (Copenhagen, Denmark) 1(3), 203-211 (2000).
34. Sugita M, Porcelli SA, Brenner MB: Assembly and retention of CD1b heavy chains in the endoplasmic reticulum. J. Immunol. 159(5), 2358-2365 (1997).
35. Gadola SD, Zaccai NR, Harlos K et al.: Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat. Immunol. 3(8), 721-726 (2002).
36. Batuwangala T, Shepherd D, Gadola SD et al.: The crystal structure of human CD1b with a bound bacterial glycolipid. J. Immunol. 172(4), 2382-2388 (2004).
37. Moody DB, Ulrichs T, Muhlecker W et al.: CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404(6780), 884-888 (2000).
38. Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G: Presentation of the same glycolipid by different CD1 molecules. J. Exp. Med. 195(8), 1013-1021 (2002).
39. van den Elzen P, Garg S, Leon L et al.: Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437(7060), 906-910 (2005).
40. Winau F, Schwierzeck V, Hurwitz R et al.: Saposin C is required for lipid presentation by human CD1b. Nat. Immunol. 5(2), 169-174 (2004).
41. Kang SJ, Cresswell P: Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5(2), 175-181 (2004).
42. Yuan W, Qi X, Tsang P et al.: Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc. Natl Acad. Sci. USA 104(13), 5551-5556 (2007).
43. Zhou D, Cantu C 3rd, Sagiv Y et al.: Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303(5657), 523-527 (2004).
44. Bai L, Sagiv Y, Liu Y et al.: Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen aGalCer. Proc. Natl Acad. Sci. USA 106(25), 10254-10259 (2009).
45. Steinman L: Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85(3), 299-302 (1996).
46. Engelhardt B, Ransohoff RM: The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26(9), 485-495 (2005).
47. Alt C, Laschinger M, Engelhardt B: Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 32(8), 2133-2144 (2002).
48. Columba-Cabezas S, Serafini B, Ambrosini E, Aloisi F: Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol. 13(1), 38-51 (2003).
49. Greter M, Heppner FL, Lemos MP et al.: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11(3), 328-334 (2005).
50. Racke MK, Scott DE, Quigley L et al.: Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96(5), 2195-2203 (1995).
51. Weinberg AD, Wegmann KW, Funatake C, Whitham RH: Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162(3), 1818-1826 (1999).
52. Frohman EM, Filippi M, Stuve O et al.: Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch. Neurol. 62(9), 1345-1356 (2005).
53. Chekhonin VP, Semenova AV, Gurina OI, Dmitrieva TB: Myelin oligodendrogliocyte glycoprotein: the structure, functions, role in pathogenesis of demyelinating disorders. Biomed. Khim. 49(5), 411-423 (2003).
54. Quarles RH: Myelin-associated glycoprotein (MAG): past, present and beyond. J. Neurochem. 100(6), 1431-1448 (2007).
55. Jaskiewicz E: Epitopes on myelin proteins recognized by autoantibodies present in multiple sclerosis patients. Postepy Hig. Med. Dosw. (Online) 58, 472-482 (2004).
56. Johns TG, Bernard CC: The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem. 72(1), 1-9 (1999).
57. Meinl E, Hohlfeld R: Immunopathogenesis of multiple sclerosis: MBP and beyond. Clin. Exp. Immunol. 128(3), 395-397 (2002).
58. Tzakos AG, Troganis A, Theodorou V et al.: Structure and function of the myelin proteins: current status and perspectives in relation to multiple sclerosis. Curr. Med. Chem. 12(13), 1569-1587 (2005).
59. Sobel RA, Greer JM, Kuchroo VK: Minireview: autoimmune responses to myelin proteolipid protein. Neurochem. Res. 19(8), 915-921 (1994).
60. Musse AA, Harauz G: Molecular 'negativity' may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. Int. Rev. Neurobiol. 79, 149-172 (2007).
61. Quarles RH: Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell. Mol. Life Sci. 59(11), 1851-1871 (2002).
62. Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP: Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J. Allergy Clin. Immunol. 116(2), 453-459 (2005).
63. Mata S, Lolli F, Soderstrom M, Pinto F, Link H: Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult. Scler. 5(6), 379-388 (1999).
64. Sadatipour BT, Greer JM, Pender MP: Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann. Neurol. 44(6), 980-983 (1998).
65. Acarin N, Rio J, Fernandez AL et al.: Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol. Scand. 93(2-3), 99-103 (1996).
66. Ilyas AA, Chen ZW, Cook SD: Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 139(1-2), 76-80 (2003).
67. Ryberg B: Multiple specificities of antibrain antibodies in multiple sclerosis and chronic myelopathy. J. Neurol. Sci. 38(3), 357-382 (1978).
68. Sugiyama Y, Yamamoto T: Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J. Exp. Med. 178(3), 203-215 (1996).
69. Kanter JL, Narayana S, Ho PP et al.: Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12(1), 138-143 (2006). Identification of lipid and oxidized lipid antigens reactive with IgG in multiple sclerosis cerebrospinal fluid.
70. Zheng W, Kollmeyer J, Symolon H et al.: Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta 1758(12), 1864-1884 (2006).
71. Taha TA, Mullen TD, Obeid LM: A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim. Biophys. Acta 1758(12), 2027-2036 (2006).
72. Stoffel W, Bosio A: Myelin glycolipids and their functions. Curr. Opin. Neurobiol. 7(5), 654-661 (1997).
73. Schenck M, Carpinteiro A, Grassme H, Lang F, Gulbins E: Ceramide: physiological and pathophysiological aspects. Arch. Biochem. Biophys. 462(2), 171-175 (2007).
74. Obeid LM, Hannun YA: Ceramide: a stress signal and mediator of growth suppression and apoptosis. J. Cell. Biochem. 58(2), 191-198 (1995).
75. Pettus BJ, Chalfant CE, Hannun YA: Sphingolipids in inflammation: roles and implications. Curr. Mol. Med. 4(4), 405-418 (2004).
76. Merrill AH Jr, Schmelz EM, Dillehay DL et al.: Sphingolipids - the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmacol. 142(1), 208-225 (1997).
77. Kronke M: Involvement of sphingomyelinases in TNF signaling pathways. Chem. Phys. Lipids 102(1-2), 157-166 (1999).
78. Kolesnick RN: Sphingomyelin and derivatives as cellular signals. Prog. Lipid Res. 30(1), 1-38 (1991).
79. Hannun YA, Obeid LM, Wolff RA: The novel second messenger ceramide: identification, mechanism of action, and cellular activity. Adv. Lipid Res. 25, 43-64 (1993).
80. Wirguin I, Brenner T, Steinitz M, Abramsky O: In vitro synthesis of antibodies to myelin antigens by Epstein-Barr virus-transformed B lymphocytes from patients with neurologic disorders. J. Neurol. Sci. 104(1), 92-96 (1991).
81. Richert JR, Robinson ED, Reuben-Burnside CA et al.: Measles virus-specific human T cell clones: studies of alloreactivity and antigenic cross-reactivity. J. Neuroimmunol. 19(1-2), 59-68 (1988).
82. Mameli G, Astone V, Arru G et al.: Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not human herpesvirus 6. J. Gen. Virol. 88(Pt 1), 264-274 (2007).
83. Lunemann JD, Edwards N, Muraro PA et al.: Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129(Pt 6), 1493-1506 (2006).
84. Serafini B, Rosicarelli B, Franciotta D et al.: Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204(12), 2899-2912 (2007).
85. Vartdal F, Vandvik B, Norrby E: Viral and bacterial antibody responses in multiple sclerosis. Ann. Neurol. 8(3), 248-255 (1980).
86. Vartdal F, Vandvik B: Multiple sclerosis: subclasses of intrathecally synthesized IgG and measles and varicella zoster virus IgG antibodies. Clin. Exp. Immunol. 54(3), 641-647 (1983).
87. Salmi A, Reunanen M, Ilonen J, Panelius M: Intrathecal antibody synthesis to virus antigens in multiple sclerosis. Clin. Exp. Immunol. 52(2), 241-249 (1983).
88. Burgoon MP, Williamson RA, Owens GP et al.: Cloning the antibody response in humans with inflammatory CNS disease: isolation of measles virus-specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain. J. Neuroimmunol. 94(1-2), 204-211 (1999).
89. Cremer NE, Johnson KP, Fein G, Likosky WH: Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods. Arch. Neurol. 37(10), 610-615 (1980).
90. von Herrath MG, Fujinami RS, Whitton JL: Microorganisms and autoimmunity: making the barren field fertile? Nat. Rev. Microbiol. 1(2), 151-157 (2003).
91. Wucherpfennig KW: Mechanisms for the induction of autoimmunity by infectious agents. J. Clin. Invest. 108(8), 1097-1104 (2001).
92. Oldstone MB: Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr. Top. Microbiol. Immunol. 296, 1-17 (2005). Early exposition of the possible role of molecular mimicry in the relationship of infection with autoimmune disease in man.
93. van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ: Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J. Neuroimmunol. 105(1), 46-57 (2000).
94. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ: Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann. Neurol. 53(2), 189-197 (2003).
95. Sospedra M, Martin R: Molecular mimicry in multiple sclerosis. Autoimmunity 39(1), 3-8 (2006).
96. McCoy L, Tsunoda I, Fujinami RS: Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 39(1), 9-19 (2006).
97. Barnett LA, Fujinami RS: Molecular mimicry: a mechanism for autoimmune injury. FASEB J. 6(3), 840-844 (1992).
98. Oldstone MB: Molecular mimicry and immune-mediated diseases. FASEB J. 12(13), 1255-1265 (1998).
99. McLean BN, Luxton RW, Thompson EJ: A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 113(Pt 5), 1269-1289 (1990).
100. Correale J, de los Milagros Bassani Molinas M: Oligoclonal bands and antibody responses in multiple sclerosis. J. Neurol. 249(4), 375-389 (2002).
101. Antel J, Bar-Or A: Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J. Neuroimmunol. 180(1-2), 3-8 (2006). Recent review of the possible roles of B cells and immunoglobulins in multiple sclerosis.
102. Melendez-Vasquez C, Redford J, Choudhary PP et al.: Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 73(1-2), 124-134 (1997).
103. Goodyear CS, O'Hanlon GM, Plomp JJ et al.: Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104(6), 697-708 (1999).
104. Yuki N: Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barre syndrome and Miller Fisher syndrome. J. Infect. Dis. 176(Suppl. 2), S150-S153 (1997).
105. Yuki N, Miyatake T: Guillain-Barre syndrome and Fisher's syndrome following Campylobacter jejuni infection. Ann. NY Acad. Sci. 845, 330-340 (1998).
106. Prendergast MM, Willison HJ, Moran AP: Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross-reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect. Immun. 67(7), 3698-3701 (1999). Good example of the support for glycolipid-based molecular mimicry to Campylobacter jejuni bacterial infection and autoimmune disease, the Guillain-Barré syndrome, in the human peripheral nervous system.
107. Sack DA, Lastovica AJ, Chang SH, Pazzaglia G: Microtiter assay for detecting Campylobacter spp. and Helicobacter pylori with surface gangliosides which bind cholera toxin. J. Clin. Microbiol. 36(7), 2043-2045 (1998).
108. Mori M, Kuwabara S, Miyake M et al.: Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barre syndrome. Neurology 52(6), 1282-1284 (1999).
109. Yu RK, Ariga T: The role of glycosphingolipids in neurological disorders. Mechanisms of immune action. Ann. NY Acad. Sci. 845, 285-306 (1998).
110. Katzenellenbogen E, Kocharova NA, Korzeniowska-Kowal A et al.: Immunochemical studies of the lipopolysaccharides of Hafnia alvei PCM 1219 and other strains with the O-antigens containing d-glucose 1-phosphate and 2-deoxy-2-[(R)-3-hydroxybutyramido]-d-glucose. Arch. Immunol. Ther. Exp. (Warsz.) 56(5), 347-352 (2008).
111. Parolis H, Parolis LA, Olivieri G: Structural studies on the Shigella-like Escherichia coli O121 O-specific polysaccharide. Carbohydr. Res. 303(3), 319-325 (1997).
112. Ali T, Weintraub A, Widmalm G: Structural determination of the O-antigenic polysaccharide from the Shiga toxin-producing Escherichia coli O171. Carbohydr. Res. 341(11), 1878-1883 (2006).
113. Sidorczyk Z, Toukach FV, Zych K et al.: Structural and serological relatedness of the O-antigens of Proteus penneri 1 and 4 from a novel Proteus serogroup O72. Eur. J. Biochem. 269(1), 358-363 (2002).
114. Kubler-Kielb J, Vinogradov E, Chu C, Schneerson R: O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a. Carbohydr. Res. 342(3-4), 643-647 (2007).
115. Schroder NW, Schombel U, Heine H, Gobel UB, Zahringer U, Schumann RR: Acylated cholesteryl galactoside as a novel immunogenic motif in Borrelia burgdorferi sensu stricto. J. Biol. Chem. 278(36), 33645-33653 (2003).
116. Yildirim HH, Li J, Richards JC, Hood DW, Moxon ER, Schweda EK: Complex O-acetylation in non-typeable Haemophilus influenzae lipopolysaccharide: evidence for a novel site of O-acetylation. Carbohydr. Res. 340(17), 2598-2611 (2005).
117. MacLean LL, Webb AC, Perry MB: Structural elucidation of the O-antigenic polysaccharide from enterohemorrhagic (EHEC) Escherichia coli O48:H21. Carbohydr. Res. 341(15), 2543-2549 (2006).
118. Compston A: Complexity and heterogeneity in demyelinating disease. Brain 130(Pt 5), 1178-1180 (2007).
119. Lassmann H, Bruck W, Lucchinetti C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7(3), 115-121 (2001).
120. Walker LS, Abbas AK: The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2(1), 11-19 (2002).
121. Ben-Nun A, Wekerle H, Cohen IR: Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292(5818), 60-61 (1981).
122. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr: Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184(6), 2271-2278 (1996).
123. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T: Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186(10), 1677-1687 (1997).
124. Van Kaer L: Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol. Cell Biol. 82(3), 315-322 (2004).
125. Linsen L, Somers V, Stinissen P: Immunoregulation of autoimmunity by natural killer T cells. Hum. Immunol. 66(12), 1193-1202 (2005).
126. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L: NKT cells: what's in a name? Nat. Rev. Immunol. 4(3), 231-237 (2004).
127. O'Keeffe J, Gately CM, Counihan T et al.: T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to a-galactosylceramide are impaired. J. Neurol. Sci. 275(1-2), 22-28 (2008).
128. + natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J. Immunol. 163(4), 2314-2321 (1999).
129. Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ: Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J. Immunol. 173(6), 3725-3731 (2004).
130. Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23, 877-900 (2005).
131. Carding SR, Egan PJ: gd T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2(5), 336-345 (2002).
132. Zajonc DM, Elsliger MA, Teyton L, Wilson IA: Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat. Immunol. 4(8), 808-815 (2003).
133. Zajonc DM, Crispin MD, Bowden TA et al.: Molecular mechanism of lipopeptide presentation by CD1a. Immunity 22(2), 209-219 (2005).
134. Zajonc DM, Cantu C 3rd, Mattner J et al.: Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 6(8), 810-818 (2005).
135. Koch M, Stronge VS, Shepherd D et al.: The crystal structure of human CD1d with and without a-galactosylceramide. Nat. Immunol. 6(8), 819-826 (2005).
136. Giabbai B, Sidobre S, Crispin MD et al.: Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation. J. Immunol. 175(2), 977-984 (2005).
137. Moody DB, Zajonc DM, Wilson IA: Anatomy of CD1-lipid antigen complexes. Nat. Rev. Immunol. 5(5), 387-399 (2005).
138. Miyamoto K, Miyake S, Yamamura T: A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413(6855), 531-534 (2001).
139. Parekh VV, Singh AK, Wilson MT et al.: Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173(6), 3693-3706 (2004).
140. Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW Jr, Murphy WJ, Wiltrout RH: Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172(2), 943-953 (2004).
141. Godfrey DI, Kronenberg M: Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114(10), 1379-1388 (2004). Recent review of the role of glycolipid-reactive invariant natural killer T cells in the regulation of immune responsiveness.
142. Wilson SB, Delovitch TL: Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3(3), 211-222 (2003).
143. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T: Differential expression of NK T cell V α 24J α Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164(8), 4375-4381 (2000).
144. + T-cell repertoire leads to circulating NKT-cell defects in a multiple sclerosis patient at the onset of his disease. Immunol. Lett. 90(2-3), 223-228 (2003).
145. + NKT cells derived from multiple sclerosis in remission. Int. Immunol. 15(2), 279-288 (2003).
146. + NKT lymphocytes are activated memory cells. Eur. J. Immunol. 30(6), 1544-1550 (2000).
147. van Der Vliet HJ, Nishi N, de Gruijl TD et al.: Human natural killer T cells acquire a memory-activated phenotype before birth. Blood 95(7), 2440-2442 (2000).
148. Miyake S, Yamamura T: Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5(3), 315-322 (2005).
149. Mars LT, Gautron AS, Novak J et al.: Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J. Immunol. 181(4), 2321-2329 (2008).
150. Winkler-Pickett R, Young HA, Cherry JM et al.: In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J. Immunol. 180(7), 4495-4506 (2008).
151. Singh AK, Wilson MT, Hong S et al.: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1801-1811 (2001).
152. Pal E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T: Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V α 14 NK T cells. J. Immunol. 166(1), 662-668 (2001).
153. Jahng AW, Maricic I, Pedersen B et al.: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1789-1799 (2001).
154. Furlan R, Bergami A, Cantarella D et al.: Activation of invariant NKT cells by αGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-γ. Eur. J. Immunol. 33(7), 1830-1838 (2003).
155. Kinjo Y, Wu D, Kim G et al.: Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434(7032), 520-525 (2005).
156. Kinjo Y, Tupin E, Wu D et al.: Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7(9), 978-986 (2006).
157. Zhou D, Mattner J, Cantu C 3rd et al.: Lysosomal glycosphingolipid recognition by NKT cells. Science 306(5702), 1786-1789 (2004).
158. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V: Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199(7), 947-957 (2004).
159. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB: Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198(1), 173-181 (2003).
160. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G: Self glycolipids as T-cell autoantigens. Eur. J. Immunol. 29(5), 1667-1675 (1999).
161. Shamshiev A, Donda A, Prigozy TI et al.: The αα T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity 13(2), 255-264 (2000).
162. Zajonc DM, Maricic I, Wu D et al.: Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202(11), 1517-1526 (2005).
163. Gumperz JE, Roy C, Makowska A et al.: Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12(2), 211-221 (2000).
164. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683-747 (2005).
165. Prat A, Antel J: Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18(3), 225-230 (2005).
166. Battistini L, Fischer FR, Raine CS, Brosnan CF: CD1b is expressed in multiple sclerosis lesions. J. Neuroimmunol. 67(2), 145-151 (1996).
167. De Libero G, Macdonald HR, Dellabona P: T cell recognition of lipids: quo vadis? Nat. Immunol. 8(3), 223-227 (2007).
168. Yu KO, Im JS, Molano A et al.: Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl Acad. Sci. USA 102(9), 3383-3388 (2005).
169. Halder RC, Jahng A, Maricic I, Kumar V: Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem. Res. 32(2), 257-262 (2007).
170. Kolodny E, De Gasper R, GamaSosa MA, Weinreb HJ, Herbert J: Antisulfatide immunoglobulin G is elevated in the serum of multiple sclerosis patients. Ann. Neurol. 38, 340 (1995).
171. Kirschning E, Rutter G, Uhlig H, Dernick R: A sulfatide-reactive human monoclonal antibody obtained from a multiple sclerosis patient selectively binds to the surface of oligodendrocytes. J. Neuroimmunol. 56(2), 191-200 (1995).
172. 2+ responses in oligodendrocytes. J. Neurosci. Res. 30(4), 699-711 (1991).
173. Rosenbluth J, Moon D: Dysmyelination induced in vitro by IgM antisulfatide and antigalactocerebroside monoclonal antibodies. J. Neurosci. Res. 71(1), 104-109 (2003).
174. Bansal R, Pfeiffer SE: Reversible inhibition of oligodendrocyte progenitor differentiation by a monoclonal antibody against surface galactolipids. Proc. Natl Acad. Sci. USA 86(16), 6181-6185 (1989).
175. Dupree JL, Coetzee T, Suzuki K, Popko B: Myelin abnormalities in mice deficient in galactocerebroside and sulfatide. J. Neurocytol. 27(9), 649-659 (1998).
176. Marcus J, Popko B: Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim. Biophys. Acta 1573(3), 406-413 (2002).
177. Ishibashi T, Dupree JL, Ikenaka K et al.: A myelin galactolipid,
178. Marcus J, Honigbaum S, Shroff S, Honke K, Rosenbluth J, Dupree JL: Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 53(4), 372-381 (2006).
179. Jeon SB, Yoon HJ, Park SH, Kim IH, Park EJ: Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brain-resident immune cells. J. Immunol. 181(11), 8077-8087 (2008).
180. Stevens A, Weller M, Wietholter H: CSF and serum ganglioside antibody patterns in MS. Acta Neurol. Scand. 86(5), 485-489 (1992).
181. Pender MP, Csurhes PA, Wolfe NP et al.: Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J. Clin. Neurosci. 10(1), 63-66 (2003).
182. Valentino P, Labate A, Nistico R et al.: Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. Mult. Scler. 15(1), 114-115 (2009).
183. Giovannoni G, Morris PR, Keir G: Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Ann. Neurol. 47(5), 684-685 (2000).
184. Ruf P, Jager M, Ellwart J, Wosch S, Kusterer E, Lindhofer H: Two new trifunctional antibodies for the therapy of human malignant melanoma. Int. J. Cancer 108(5), 725-732 (2004).
185. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD: Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57(7), 1248-1252 (2001).
186. Bjartmar C, Trapp BD: Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox. Res. 5(1-2), 157-164 (2003).
187. Zaprianova E, Deleva D, Ilinov P et al.: Serum ganglioside patterns in multiple sclerosis. Neurochem. Res. 26(2), 95-100 (2001).
188. Roussel V, Yi F, Jauberteau MO et al.: Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J. Autoimmun. 14(3), 259-265 (2000).
189. Cordoliani MA, Michon-Pasturel U, Rerat K et al.: Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients. Rev. Med. Interne 19(9), 635-639 (1998).
190. D'Olhaberriague L, Levine SR, Salowich-Palm L et al.: Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology 51(5), 1376-1380 (1998).
191. Tourbah A, Clapin A, Gout O et al.: Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch. Neurol. 55(4), 517-521 (1998).
192. Lolli F, Mata S, Baruffi MC, Amaducci L: Cerebrospinal fluid anti-cardiolipin antibodies in neurological diseases. Clin. Immunol. Immunopathol. 59(2), 314-321 (1991).
193. Chaleomchan W, Hemachudha T, Sakulramrung R, Deesomchok U: Anticardiolipin antibodies in patients with rabies vaccination induced neurological complications and other neurological diseases. J. Neurol. Sci. 96(2-3), 143-151 (1990).
194. Marchiori PE, Dos Reis M, Quevedo ME et al.: Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barre syndrome and systemic lupus erythematosus. Arq. Neuropsiquiatr. 48(4), 465-468 (1990).
195. Karussis D, Leker RR, Ashkenazi A, Abramsky O: A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann. Neurol. 44(4), 629-634 (1998).
196. Tartaglia MC, Narayanan S, De Stefano N et al.: Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J. Neurol. 249(10), 1382-1390 (2002).
197. Qin J, Goswami R, Balabanov R, Dawson G: Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J. Neurosci. Res. 85(5), 977-984 (2007).
198. Woodruff RH, Franklin RJ: Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: a comparative study. Glia 25(3), 216-228 (1999).
199. Villar LM, Sadaba MC, Roldan E et al.: Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115(1), 187-194 (2005).
200. O'Keeffe J, Doherty DG, Kenna T et al.: Diverse populations of T cells with NK cell receptors accumulate in the human intestine in health and in colorectal cancer. Eur. J. Immunol. 34(8), 2110-2119 (2004).
201. Kenna T, Golden-Mason L, Porcelli SA et al.: NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171(4), 1775-1779 (2003).
202. O'Keeffe J, Gately CM, Counihan T et al.: T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to α-galactosylceramide are impaired. J. Neurol. Sci. 275(1-2), 22-28 (2008).
203. + T cells closely correlates with CD56 surface expression. J. Immunol. 164(3), 1148-1152 (2000).
204. Loza MJ, Metelitsa LS, Perussia B: NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur. J. Immunol. 32(12), 3453-3462 (2002).
205. Exley M, Porcelli S, Furman M, Garcia J, Balk S: CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V α 24 J α Q T cell receptor α chains. J. Exp. Med. 188(5), 867-876 (1998).
206. + human T lymphocytes. Direct evidence that the NKRP1A molecule is involved in transendothelial migration. Eur. J. Immunol. 27(9), 2345-2350 (1997).
207. + T cell responses. Nat. Immunol. 3(2), 189-195 (2002).
208. Lee N, Llano M, Carretero M et al.: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95(9), 5199-5204 (1998).
209. Bauer S, Groh V, Wu J et al.: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285(5428), 727-729 (1999).
210. Van Kaer L: α-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5(1), 31-42 (2005).